[2-(4-Cyclopropylbenzyl)phenyl]-5a-carba-beta-D-glucopyranoside

ID: ALA1819489

Chembl Id: CHEMBL1819489

PubChem CID: 11516541

Max Phase: Preclinical

Molecular Formula: C23H28O5

Molecular Weight: 384.47

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  OC[C@H]1C[C@@H](Oc2ccccc2Cc2ccc(C3CC3)cc2)[C@H](O)[C@@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C23H28O5/c24-13-18-12-20(22(26)23(27)21(18)25)28-19-4-2-1-3-17(19)11-14-5-7-15(8-6-14)16-9-10-16/h1-8,16,18,20-27H,9-13H2/t18-,20-,21-,22+,23+/m1/s1

Standard InChI Key:  XCRLWQNVUFAWND-FXILAVBZSA-N

Associated Targets(Human)

SLC5A4 Tchem Low affinity sodium-glucose cotransporter (30 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC5A1 Tclin Sodium/glucose cotransporter 1 (1526 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 384.47Molecular Weight (Monoisotopic): 384.1937AlogP: 2.00#Rotatable Bonds: 6
Polar Surface Area: 90.15Molecular Species: NEUTRALHBA: 5HBD: 4
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 12.79CX Basic pKa: CX LogP: 2.23CX LogD: 2.23
Aromatic Rings: 2Heavy Atoms: 28QED Weighted: 0.61Np Likeness Score: 1.10

References

1. Ohtake Y, Sato T, Matsuoka H, Nishimoto M, Taka N, Takano K, Yamamoto K, Ohmori M, Higuchi T, Murakata M, Kobayashi T, Morikawa K, Shimma N, Suzuki M, Hagita H, Ozawa K, Yamaguchi K, Kato M, Ikeda S..  (2011)  5a-Carba-β-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.,  19  (18): [PMID:21873071] [10.1016/j.bmc.2011.08.005]

Source